title: Circulating miRNA profiles in patients with metabolic syndrome.
abstract: BACKGROUND
  Coordinated interplay of dysregulated microRNAs in isolated metabolic disorder is implicated in the pathogenesis of metabolic syndrome.
  
  
  OBJECTIVE
  The objective of the study was to characterize microRNA expression in the blood and exosomes of individuals with metabolic syndrome and compare them with those manifesting one of the metabolic vascular risk factors (type 2 diabetes, hypercholesterolemia, or hypertension). RESEARCH DESIGN/SETTING/PARTICIPANTS: A total of 265 participants were recruited in a health screening and characterized into distinct groups as follows: 1) healthy controls (n = 46); 2) metabolic syndrome (n = 50); 3) type 2 diabetes (n = 50); 4) hypercholesterolemia (n = 89); and 5) hypertension (n = 30). Total RNA was subjected to microRNA profiling, and a panel of significantly dysregulated microRNAs was validated using quantitative PCR.
  
  
  METHODS
  Analysis of profiling data characterized unique pools of miRNAs that could categorize the different risk factors of metabolic syndrome.
  
  
  RESULTS
  We have identified miR-197, miR-23a, and miR-509-5p as potential contributors of dyslipidemia in metabolic syndrome (correlation with body mass index; P = 0.029, 0.021, and 0.042, respectively) and miR-130a and miR-195 as contributors of hypertension (correlation with blood pressure; P = 0.019 and 0.045, respectively). A plausible association of miR-27a and miR-320a with metabolic syndrome and type 2 diabetes patients has also been found because these miRNAs remained dysregulated in both cases (correlation with fasting glucose; P = 0.010 and 0.016, respectively).
  
  
  CONCLUSIONS
  Significant dysregulation of seven candidate microRNAs has been found to be associated with risks involved in the manifestation of metabolic syndrome.
authors.affiliation: Department of Biochemistry, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, 8 Medical Drive, Singapore 117597.
authors.forename: Dwi Setyowati
authors.initials: DS
authors.lastname: Karolina
authors.forename: Subramaniam
authors.initials: S
authors.lastname: Tavintharan
authors.forename: Arunmozhiarasi
authors.initials: A
authors.lastname: Armugam
authors.forename: Sugunavathi
authors.initials: S
authors.lastname: Sepramaniam
authors.forename: Sharon Li Ting
authors.initials: SL
authors.lastname: Pek
authors.forename: Michael T K
authors.initials: MT
authors.lastname: Wong
authors.forename: Su Chi
authors.initials: SC
authors.lastname: Lim
authors.forename: Chee Fang
authors.initials: CF
authors.lastname: Sum
authors.forename: Kandiah
authors.initials: K
authors.lastname: Jeyaseelan
mesh_terms: D016022:Case-Control Studies; D016000:Cluster Analysis; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000235:genetics; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000235:genetics; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000235:genetics; D024821:Metabolic Syndrome / Q000097:blood* / Q000209:etiology / Q000235:genetics*; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D046228:Microarray Analysis; D008954:Models, Biological; D012307:Risk Factors; D059467:Transcriptome; D054928:Validation Studies as Topic
chemical_list: D035683:MicroRNAs